Objective: To compare the Ki-67 index of endometrial cancer cells before and after treatment between the metformin and placebo group in women with endometrial cancer (EC). Methods: This study was a randomized, double-blind, placebo-controlled trial conducting in non-diabetic women who diagnosed with endometrioid EC and had a schedule for elective surgical staging at Rajavithi Hospital between August 2018 and June 2019. Tissue specimens were obtained via endometrial curettage at the time of initial diagnosis (pre-treatment) and hysterectomy (post-treatment) to assess the value of the Ki-67 index by immunochemistry. Patients were randomly assigned into 2 groups: metformin and placebo group. Metformin 850 mg or placebo 1 tab were administered once daily for at least 7 days, starting on the first morning after recruitment until one day before surgery. Baseline characteristics (e.g., age, body mass index, co-morbidities) including surgical and pathological characteristics were recorded. The metabolic effect of metformin was also evaluated by a recording of fasting blood sugar, HbA1C and potential adverse events including nausea, vomiting, dizziness, and hypoglycemic symptom. Results: A total of 49 EC patients were included in this study. Twenty-five patients were assigned to the metformin group and 24 patients were assigned to the placebo group. Baseline demographic, surgical, and pathological characteristics between the 2 groups were similar. Metformin significantly changed the Ki-67 index relative to placebo, with a mean decrease of 23.3% (p=0.001) and a mean proportional decrease of 39.1% (p=0.006) before and after treatment. Additionally, no significant differences were detected in metabolic effects and adverse events between the metformin and the placebo groups. Conclusion: Short-term treatment with an oral metformin significantly reduced a proliferative marker Ki-67 index in women with endometrioid EC awaiting surgical staging. This study supports the biological effect of metformin in EC and potential applications in the adjuvant treatment in EC patients.
Petchsila, K., Prueksaritanond, N., Insin, P., Yanaranop, M., & Chotikawichean, N. (2020). Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial. Asian Pacific Journal of Cancer Prevention, 21(3), 733-741. doi: 10.31557/APJCP.2020.21.3.733
MLA
Kittisak Petchsila; Nisa Prueksaritanond; Putsarat Insin; Marut Yanaranop; Nutpacha Chotikawichean. "Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial". Asian Pacific Journal of Cancer Prevention, 21, 3, 2020, 733-741. doi: 10.31557/APJCP.2020.21.3.733
HARVARD
Petchsila, K., Prueksaritanond, N., Insin, P., Yanaranop, M., Chotikawichean, N. (2020). 'Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial', Asian Pacific Journal of Cancer Prevention, 21(3), pp. 733-741. doi: 10.31557/APJCP.2020.21.3.733
VANCOUVER
Petchsila, K., Prueksaritanond, N., Insin, P., Yanaranop, M., Chotikawichean, N. Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial. Asian Pacific Journal of Cancer Prevention, 2020; 21(3): 733-741. doi: 10.31557/APJCP.2020.21.3.733
)